Toronto, Canada (PRWEB) July 24, 2014
The first part of the session on “Best Practices for Optimizing Dose Escalation in First in Human Studies” will cover comprehensive clinical support in early phase studies to make better go/no-go decisions.
With increasing R&D costs and declining industry success in getting products to market, pharmaceutical companies need to maximize the knowledge collected in early Phase I/IIa study data to make better go/no-go decisions and improve success in late stage development.
Next, the presenters will examine steps to improve your dose selection and ultimately the value of your early clinical data. Using illustrative scenarios, they will explore key protocol design considerations along with essential pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation techniques.
Identifying the best dose escalation scheme in FIH studies is a critical and often underestimated step in early development decision-making. Likewise, setting up ideal study collection procedures is key to getting the most out of the subject data to efficiently produce an accurate understanding of your compound’s strengths and susceptibilities.
John the presenters, Dr. Seth Berry, Director, Clinical PK/PD Modeling & Simulation, & Center for Statistics in Drug Development at Quintiles, and Professor Tim Mant, Vice President, Medical Research and Principal Investigator at Quintiles, as they examine ways to:
Viewers will gain an understanding of ways to make the most of your early clinical development -- from efficiently conducting
Copyright©2014 Vocus, Inc.
All rights reserved